1-methoxy-3-(3-methyl-butyloxy) benzene | 1005005-54-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-methoxy-3-(3-methyl-butyloxy) benzene
• 英文别名: 1-Isopentyloxy-3-methoxybenzene；1-methoxy-3-(3-methylbutoxy)benzene
• CAS: 1005005-54-8
• 化学式: C₁₂H₁₈O₂
• 分子量: 194.274
• InChiKey: TZZJRILNDXJXGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• METHODS AND COMPOSITIONS FOR CONTROL OF GYPSY MOTHS, Lymanria dispar
  申请人：Plettner Erika

  公开号：US20100190865A1

  公开（公告）日：2010-07-29

  The invention provides in part dialkoxybenzene and eugenol compounds for controlling infestation by a Lymantria dispar , and methods thereof. The compounds include a compound of Formula I: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; R2 may be at positions 2, 3 or 4 and may be H, methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; and R3 may be optionally present at positions 2, 3 and 4, and is allyl; with the provisos that when R2 is at position 2, R3 if present is at position 3, or when R2 is at to position 3, R3 if present is at positions 2 or 4, or when R2 is at position 4, R3 if present is at position 2; or of Formula II: where R1 may be methyl, ethyl, propyl, n-butyl, isopentyl (3-methylbutyl) or allyl; or mixtures thereof.

  该发明部分提供了用于控制以及方法的苯基二甲氧基苯和丁香酚化合物对Lymantria dispar的侵害。这些化合物包括式I的化合物：其中R1可以是甲基、乙基、丙基、正丁基、异戊基（3-甲基丁基）或烯丙基；R2可以在2、3或4位，可以为H、甲基、乙基、丙基、正丁基、异戊基（3-甲基丁基）或烯丙基；R3可以选择性地存在于2、3和4位，为烯丙基；但要注意的是，当R2在2位时，如果R3存在，则在3位，或者当R2在3位时，如果R3存在，则在2或4位，或者当R2在4位时，如果R3存在，则在2位；或者式II的化合物：其中R1可以是甲基、乙基、丙基、正丁基、异戊基（3-甲基丁基）或烯丙基；或它们的混合物。
• ARGINASE INHIBITORS AND METHODS OF USE
  申请人：CHRISTIANSON DAVID W.

  公开号：US20100189644A1

  公开（公告）日：2010-07-29

  The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

  本发明涉及化合物IA或化合物IB的抑制剂，或其药用盐，含有这些化合物的组合物，以及用于治疗和诊断由精氨酸酶上调、异常高的精氨酸酶活性或异常低的一氧化氮合酶活性所特征的疾病的方法。
• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20090036444A1

  公开（公告）日：2009-02-05

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性具有抗HCV活性，是一种预防或治疗丙型肝炎的药剂。
• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。